Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine  

作　　者：Jiang-Yu Bian Yu-Fang Feng Wen-Ting He Tong Zhang 

机构地区：[1]Department of Oncology,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091,China [2]Department of Oncology,The Fourth Clinical Medical College of Xinjiang Medical University,Urumqi 830001,China [3]Department of Oncology,Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University,Urumqi 830001,China

出　　处：《World Journal of Clinical Oncology》2025年第1期25-33,共9页世界临床肿瘤学杂志（英文）

基　　金：Supported by National Natural Science Foundation of China,No.82174461;Hospital Capability Enhancement Project of Xiyuan Hospital,CACMS,No.XYZX0201-22;Technology Innovation Project of China Academy of Chinese Medical Sciences,No.CI2021A01811.

摘　　要：BACKGROUND Patients with BRAF V600E mutant metastatic colorectal cancer(mCRC)have a low incidence rate,poor biological activity,suboptimal response to conventional treatments,and a poor prognosis.In the previous cohort study on mCRC conducted by our team,it was observed that integrated Chinese and Western medicine treatment could significantly prolong the overall survival(OS)of patients with colorectal cancer.Therefore,we further explored the survival benefits in the population with BRAF V600E mutant mCRC.AIM To evaluate the efficacy of integrated Chinese and Western medicine in the treatment of BRAF V600E mutant metastatic colorectal cancer.METHODS A cohort study was conducted on patients with BRAF V600E mutant metastatic colorectal cancer admitted to Xiyuan Hospital of China Academy of Chinese Medical Sciences and Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from January 2016 to December 2022.The patients were divided into two cohorts.RESULTS A total of 34 cases were included,with 23 in Chinese-Western medicine cohort(cohort A)and 11 in Western medicine cohort(cohort B).The median overall survival was 19.9 months in cohort A and 14.2 months in cohort B,with a statistically significant difference(P=0.038,hazard ratio=0.46).The 1-3-year survival rates were 95.65%(22/23),39.13%(9/23),and 26.09%(6/23)in cohort A,and 63.64%(7/11),18.18%(2/11),and 9.09%(1/11)in cohort B,respectively.Subgroup analysis showed statistically significant differences in median OS between the two cohorts in the right colon,liver metastasis,chemotherapy,and first-line treatment subgroups(P<0.05).CONCLUSION Integrated Chinese and Western medicine can prolong the survival and reduce the risk of death in patients with BRAF V600E mutant metastatic colorectal cancer,with more pronounced benefits observed in patients with right colon involvement,liver metastasis,combined chemotherapy,and first-line treatment.

关 键 词：Metastatic colorectal cancer BRAF V600E mutation Integrated Chinese and Western medicine Cohort study 

分 类 号：R73-37[医药卫生—肿瘤]